SARS-CoV-2 Antibody Response to Vaccination in Peritoneal Dialysis Patients

• Published in: Portuguese journal of nephrology & hypertension Vol. 37; no. 4; pp. 192 - 195
• Main Authors: Donato, Beatriz, Mateus, Catarina, Roxo, Maria Inês, Duarte, Carlos Pereira, Calça, Rita Ribeiro, Matias, Patrícia João, Branco, Patrícia
• Format: Journal Article
• Language: English; Portuguese
• Published: Sociedade Portuguesa de Nefrologia 01.12.2023; Publicações Ciência e Vida
• Subjects: chronic; covid-19; covid-19 vaccines; humoral; immunity; kidney failure; peritoneal dialysis; sars-cov-2; UROLOGY & NEPHROLOGY; COVID-19; SARS-CoV-2; Kidney Failure, Chronic; Immunity, Humoral; Peritoneal Dialysis; COVID-19 Vaccines
• ISSN: 0872-0169; 2183-1289
• DOI: 10.32932/pjnh.2023.11.262

ABSTRACT Introduction: Chronic kidney disease patients have a higher risk of infection and worse clinical outcomes after coronavirus disease. We aimed to assess the prevalence of infection and the humoral response after vaccination in peritoneal dialysis patients. Methods: Three types of vaccines were administered (two doses) with the antibody detection at least six months after. Coronavirus disease 2019 infections, hospital admissions, and deaths were evaluated. Results: From 70 prevalent patients, 45 were included. There was a significant increase in antibody level, with a median of 92 (36, 447) U/mL. Only 4% of patients remained seronegative. History of immunosuppressive therapy was associated with no response (100% vs 60%, p=0.010). There were two infections after the vaccination, without hospital admission. Conclusion: Immunization against coronavirus disease was effective in generating a humoral response in peritoneal dialysis patients. There was also an evident impact of immunosuppressive therapy on vaccine response in peritoneal dialysis patients.